Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax (2021 - 2025)
Historic Long-Term Deferred Tax for Ironwood Pharmaceuticals (IRWD) over the last 5 years, with Q3 2025 value amounting to $101.7 million.
- Ironwood Pharmaceuticals' Long-Term Deferred Tax fell 4513.43% to $101.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.7 million, marking a year-over-year decrease of 4513.43%. This contributed to the annual value of $144.2 million for FY2024, which is 3206.89% down from last year.
- According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Long-Term Deferred Tax is $101.7 million, which was down 4513.43% from $129.5 million recorded in Q2 2025.
- Ironwood Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $337.8 million during Q2 2021, with a 5-year trough of $101.7 million in Q3 2025.
- Moreover, its 5-year median value for Long-Term Deferred Tax was $250.8 million (2023), whereas its average is $240.9 million.
- As far as peak fluctuations go, Ironwood Pharmaceuticals' Long-Term Deferred Tax tumbled by 510.54% in 2022, and later plummeted by 4513.43% in 2025.
- Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Long-Term Deferred Tax stood at $333.3 million in 2021, then fell by 14.89% to $283.7 million in 2022, then decreased by 25.15% to $212.3 million in 2023, then plummeted by 32.07% to $144.2 million in 2024, then dropped by 29.5% to $101.7 million in 2025.
- Its Long-Term Deferred Tax stands at $101.7 million for Q3 2025, versus $129.5 million for Q2 2025 and $143.6 million for Q1 2025.